Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010

      -- Company achieved product revenue and beat gross margin dollar guidance for 2010 --


      News provided by

      Verenium Corporation

      Mar 01, 2011, 04:01 ET

      Share this article

      Share this article


      SAN DIEGO, March 1, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported a summary of recent Company highlights and financial results for the fourth quarter and year ended December 31, 2010.

      "2010 was a year of significant progress for Verenium. Even as we completed the complex process of refocusing on our core enzymes business, we were able to achieve or exceed our growth targets for the business," said James E. Levine, President and Chief Executive Officer Designate of Verenium. "Based on the solid performance of our commercial products as well as the interest we've had from potential partners for our pipeline products, I am very enthusiastic about the many opportunities ahead. I expect 2011 will be an important year for Verenium in which we will focus on achieving our corporate goals which we believe will continue to position Verenium as a leading industrial enzymes company."

      Company Highlights

      During 2010 Verenium has made significant progress on both the operational and financial fronts.  Most recent accomplishments include:

      Operational/Industry Performance:

      Animal Health and Nutrition

      • Achieved a 25% increase in full year 2010 gross profit from Phyzyme sales over the same period in 2009 due to strong demand for Phyzyme phytase.

      Grain Processing

      • Grew full year 2010 revenues from the Company's grain processing enzymes, including Fuelzyme, Deltazym GA L-E5, Veretase and Xylathin, by 38% over the same period in 2009; and
      • Grain processing has grown to represent 27% of 2010 product revenues.

      Oilseed Processing

      • Increased Purifine® PLC plant count from one in 2009 to four at the end of 2010 and currently have five plants in the process of implementation; and
      • Announced joint marketing agreement with a second global engineering partner, Desmet Ballestra, for Purifine® PLC, and extended the partnership agreement with Alfa Laval.

      Manufacturing

      • Expanded committed fermentation capacity at Fermic, the Company's contract manufacturing partner, and launched a manufacturing improvement program to expand downstream capacity, increase manufacturing efficiency and improve overall stability of manufacturing processes.

      Corporate/Financial:

      • Increased total product revenue by 15% to $50.4 million for the year ended December 31, 2010, achieving 2010 guidance range of $48 to $54 million;
      • Increased 2010 year end product gross profit by 16% to $18.6 million, exceeding 2010 annual guidance of $16 to $18 million;
      • Increased full year non Phyzyme revenue from 25% in 2009 to 35% in 2010 through increasing sales of Company's newer enzymes including Fuelzyme, Xylathin, Veretase, Deltazym GA L-E5 and Purifine; and
      • Ended the quarter and year with unrestricted cash and cash equivalents totaling $87.9 million and convertible notes outstanding of $74.7 million.

      "We ended 2010 with a more flexible financial structure and better positioned to invest strategically and grow the industrial enzymes business," said Jeffrey G. Black, Senior Vice President and Chief Financial Officer Designate.  "In 2011 we will look to further solidify our capital structure and create a clear path to profitability through a combination of revenue and gross margin growth, pipeline development, manufacturing improvements, and strategic partnerships."

      Financial Results

      In the commentary below, the historical results of the Company's ligno-cellulosic biofuels business for current and prior periods have been reclassified into discontinued operations as a result of the sale of the ligno-cellulosic biofuels business on September 2, 2010 to BP.

      Revenues

      Revenues for the periods ended December 31, 2010 and 2009 were as follows (in thousands):



      Three Months Ended 

      December 31,


      Year Ended 

      December 31,


      2010


      2009


      2010


      2009

      Revenues:








            Animal Health and Nutrition

      $           8,051


      $          8,934


      $        32,588


      $       32,781

            Grain Processing

      3,834


      2,728


      13,439


      9,744

      All other products

      1,381


      200


      4,324


      1,431

                 Total product

      13,266


      11,862


      50,351


      43,956

      Collaborative and grant

      331


      1,494


      1,722


      4,863

      Total revenues

      $         13,597


      $        13,356


      $       52,073


      $       48,819




      Total revenues for the year ended December 31, 2010 increased 7% to $52.1 million from $48.8 million in the prior year, with product revenues representing 90% or more of total revenues in both periods. Product revenues for the year ended December 31, 2010 increased 15% to $50.4 million from $44.0 million in the prior year, primarily due to an increase in Phyzyme profit share from Danisco, as well as an increase in revenues from grain processing enzymes, Fuelzyme, Veretase, Deltazym GA L-E5 and Xylathin, which continued to gain traction in the grain ethanol markets, and Purifine enzyme for the soybean oil processing market. Product revenue from non-Phyzyme products as a percentage of total product revenue increased to 35% for the year ended December 31, 2010 compared to 25% in the prior year.

      Product Gross Profit

      Product gross profit for the year ended December 31, 2010 increased 16% to $18.6 million from $16.0 million in the prior year, primarily due to improved fixed cost leverage on higher revenue, partially offset by the impact of manufacturing constraints compared to the prior year, resulting from the challenges of satisfying increased demand for our products and expanded product mix.

      Operating Expenses (excluding cost of product revenue)

      Excluding cost of product revenues, total operating expenses related to continuing operations decreased to $33.9 million (including share-based compensation of $1.1 million) for the year ended December 31, 2010 from $35.3 million (including share-based compensation of $4.7 million) for the same period in the prior year.  Excluding the impact of share-based compensation, total operating expenses increased $2.2 million primarily due to bonus payments expensed during the year ended December 31, 2010, for which there was no corresponding expense in 2009.

      Operating Loss from Continuing Operations

      Operating loss from continuing operations for the year ended December 31, 2010 was $13.5 million compared to $14.5 million for the same period in 2009, reflective of the increase in product gross margin and a decrease in selling, general & administrative expenses. Excluding the impact of share-based compensation, total operating loss from continuing operations increased $2.6 million primarily due to bonus payments expensed during the year ended December 31, 2010, for which there was no corresponding expense in 2009.

      Net Loss from Continuing Operations

      Net loss from continuing operations for the year ended December 31, 2010 was $14.2 million compared to a net loss of $6.4 million for the same period in 2009, on a GAAP accounting basis. Adjusted for the impact of non-cash items, the Company's non-GAAP pro-forma net loss from continuing operations for the year ended December 31, 2010 was $21.0 million compared to $24.6 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

      Financial Guidance for 2011

      Verenium also updated 2011 financial guidance for R&D and SG&A expenses.  The Company re-allocated the accounting of certain expenses from R&D to SG&A, leaving the total level of operating expenses unchanged at $33 to $37 million.

      • Revenue: $55 to $60 million
      • Product Gross Profit: $21 to $24 million
      • R&D: $10 to $12 million
      • SG&A: $23 to $25 million

      Planned capital investments for the commercial business, including manufacturing debottlenecking, are expected to be between $4 and $6 million.  In addition, the Company expects to spend up to $10 million to build out a new San Diego, CA facility over the next two years and is exploring opportunities for spreading the capital expenditure over a longer period of time.

      About Verenium

      Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

      Forward-Looking Statements

      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:

      Kelly Lindenboom

      Vice President, Corporate Communications

      617-674-5335

      [email protected]

      Sarah Carmody

      Manager, Corporate Communications

      617-674-5357

      [email protected]




      Verenium Corporation

      Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)



      Three Months Ended
      December 31,


      Year Ended
      December 31,


      2010


      2009


      2010


      2009

      Revenues:








        Product

      $           13,266


      $         11,862


      $       50,351


      $           43,956

        Collaborative and grant

      331


      1,494


      1,722


      4,863

      Total revenue

      13,597


      13,356


      52,073


      48,819









      Operating expenses:








        Cost of product revenue

      8,536


      7,447


      31,715


      27,929

      Product Gross Profit

      4,730


      4,415


      18,636


      16,027

      Product Gross Margin

      36%


      37%


      37%


      36%

        Research and development

      2,068


      1,020


      6,198


      5,829

        Selling, general and administrative

      6,194


      4,649


      27,662


      29,520









      Total operating expenses

      16,798


      13,116


      65,575


      63,278









      Operating income (loss) from continuing operations

      (3,201)


      240


      (13,502)


      (14,459)









      Other Income and Expense:

        Interest and other expense, net

      (1,301)


      (1,125)


      (7,481)


      (10,105)









        Loss on debt extinguishment

      --


      --


      (3,384)


      --

        Gain on debt extinguishment upon conversion

      --


      317


      598


      8,946

        Gain on amendment of 2008 Notes

      --


      --


      --


      3,977

        Gain (loss) on net change in fair value of derivative assets and liabilities

      872


      199


      (145)


      5,277

      Total other income (expense), net

      (429)


      (609)


      (10,412)


      8,095









      Loss from continuing operations before income taxes

      (3,630)


      (369)


      (23,914)


      (6,364)

      Income tax benefit

      1,820


      --


      9,748


      --

      Net loss from continuing operations

      (1,810)


      (369)


      (14,166)


      (6,364)

      Discontinued Operations:

        Net income (loss) from discontinued operations, net of income taxes

      (1,490)


      (11,438)


      8,816


      (49,876)









      Less: Loss attributed to noncontrolling interests in consolidated entities – discontinued operations

      --


      8,849


      25,283


      34,349

      Net income (loss) attributed to Verenium

      $          (3,300)


      $          (2,958)


      $         19,933


      $       (21,891)

      Basic and diluted net income (loss) per share:

      Continuing Operations

      $           (0.14)


      $            (0.03)


      $          (1.15)


      $           (0.75)

      Discontinued Operations

      $           (0.12)


      $            (1.00)


      $            0.72


      $           (5.89)

      Net income (loss) attributed to Verenium

      $           (0.26)


      $            (0.26)


      $            1.62


      $           (2.58)

      Shares used in computing basic and diluted net income (loss) per share

      12,591


      11,493


      12,321


      8,470




      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (unaudited, in thousands)


      December 31,


      December 31,


      2010


      2009






      Cash and cash equivalents

      $          87,929


      $           24,844

      Accounts receivable, net

      6,708


      6,558

      Inventory, net

      5,316


      2,586

      Other current assets  

      2,694


      2,500

      Restricted cash

      5,000


      10,400

      Property and equipment, net  

      3,134


      4,169

      Other noncurrent assets  

      976


      2,020

      Assets of discontinued operations

      --


      114,845





      Total assets  

      $        111,757


      $          167,922









      Current liabilities, excluding deferred revenue and liabilities of discontinued operations

      $          16,849


      $            10,523

      Deferred revenue, current  

      894


      895

      Convertible notes, at carrying value (face value of $74.7 million at December 31, 2010 and $97.9 million at December 31, 2009)

      88,011


      105,756

      Other long term liabilities  

      1,216


      1,734

      Liabilities of discontinued operations  

      1,617


      18,812

      Stockholders' equity  

      3,170


      30,202





      Total liabilities, noncontrolling interests and stockholders' equity  

      $        111,757


      $         167,922








      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)


      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three months and years ended December 31, 2010 and 2009, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.


      Non-GAAP Pro Forma Net Loss From Continuing Operations




      Three Months Ended

      December 31,


      Year Ended

      December 31,


      2010


      2009


      2010


      2009









      Net loss from continuing operations

      $         (1,810)


      $              (369)


      $         (14,166)


      $            (6,364)









        Adjustments:  








         Income tax benefit

      (1,820)


      --


      (9,748)


      --

         Loss on debt extinguishment

      --


      --


      3,384


      --

      Gain on debt extinguishment upon conversion

      --


      (317)


      (598)


      (8,946)

         Gain on amendment of 2008 Notes

      --


      --


      --


      (3,977)

      (Gain) loss on net change in fair value of derivative assets and liabilities

      (872)


      (199)


      145


      (5,277)

        Non-GAAP pro forma net loss from continuing operations  

      $        (4,502)


      $               (885)


      $         (20,983)


      $          (24,564)









      Non-GAAP pro forma net loss from continuing operations per share  

      $           (0.36)


      $               (0.08)


      $           (1.70)


      $             (2.90)












      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.